Arcturus Therapeutics (NASDAQ:ARCT) Financial Overview and Price Target
- Thomas Shrader from BTIG set a price target of $48 for NASDAQ:ARCT, indicating a significant potential upside from its current trading price.
- Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate significantly.
- The company's revenue for the quarter ending December 2024 was $22.77 million, falling short of expectations and showing a decline from the previous year.
Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on developing RNA medicines for rare diseases and vaccines. The company operates within the competitive Zacks Medical - Biomedical and Genetics industry. On March 10, 2025, Thomas Shrader from BTIG set a price target of $48 for ARCT, while the stock was trading at $14.55, indicating a significant potential upside.
Despite the optimistic price target, Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate of a $0.34 loss. This represents a negative surprise of 226.47%. The loss increased from $0.32 per share a year ago, highlighting financial challenges. However, in the previous quarter, ARCT reported a loss of $0.26 per share, beating expectations of a $0.70 loss, resulting in a positive surprise of 62.86%.
Arcturus's revenue for the quarter ending December 2024 was $22.77 million, falling short of the Zacks Consensus Estimate by 60.60%. This is a decline from $33.99 million in the same quarter the previous year. Despite this miss, the company has exceeded consensus revenue estimates twice in the last four quarters, showing some resilience in its financial performance.
Currently, ARCT is trading at $14.05, a decrease of approximately 3.43% or $0.50. The stock has fluctuated between $14 and $14.54 today. Over the past year, ARCT has seen a high of $45 and a low of $14, reflecting significant volatility. The company's market capitalization is approximately $381 million, with a trading volume of 43,420 shares on the NASDAQ exchange.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 1009000 | 0.59 |
| 068270.KS | 168900 | 5.03 |
| 196170.KQ | 392500 | 5.1 |
| 091990.KQ | 75900 | 0 |
Arcturus Therapeutics (NASDAQ:ARCT) Financial Overview and Price Target
- Thomas Shrader from BTIG set a price target of $48 for NASDAQ:ARCT, indicating a significant potential upside from its current trading price.
- Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate significantly.
- The company's revenue for the quarter ending December 2024 was $22.77 million, falling short of expectations and showing a decline from the previous year.
Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on developing RNA medicines for rare diseases and vaccines. The company operates within the competitive Zacks Medical - Biomedical and Genetics industry. On March 10, 2025, Thomas Shrader from BTIG set a price target of $48 for ARCT, while the stock was trading at $14.55, indicating a significant potential upside.
Despite the optimistic price target, Arcturus reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate of a $0.34 loss. This represents a negative surprise of 226.47%. The loss increased from $0.32 per share a year ago, highlighting financial challenges. However, in the previous quarter, ARCT reported a loss of $0.26 per share, beating expectations of a $0.70 loss, resulting in a positive surprise of 62.86%.
Arcturus's revenue for the quarter ending December 2024 was $22.77 million, falling short of the Zacks Consensus Estimate by 60.60%. This is a decline from $33.99 million in the same quarter the previous year. Despite this miss, the company has exceeded consensus revenue estimates twice in the last four quarters, showing some resilience in its financial performance.
Currently, ARCT is trading at $14.05, a decrease of approximately 3.43% or $0.50. The stock has fluctuated between $14 and $14.54 today. Over the past year, ARCT has seen a high of $45 and a low of $14, reflecting significant volatility. The company's market capitalization is approximately $381 million, with a trading volume of 43,420 shares on the NASDAQ exchange.
Arcturus Therapeutics Reports Q4 Earnings, Shares Jump 30%
Arcturus Therapeutics (NASDAQ:ARCT) saw a 30% surge in its share prices yesterday after reporting Q4 results. The company's revenue for the quarter was $160.3 million, a significant increase from $13.4 million in Q4/22. The boost in revenue was primarily due to the $200 million upfront payment from CSL Seqirus as part of their exclusive global collaboration and license agreement for next-generation mRNA vaccines.
Arcturus is eligible for potential development and commercial milestones of up to $4.3 billion, with 40% profit sharing for COVID-19 vaccines and up to low double-digit royalties on influenza vaccine revenues.
Joseph Payne, the President and CEO of Arcturus Therapeutics, reported that the Phase 3 study conducted by Meiji Pharma to evaluate ARCT-154 as a booster vaccine for COVID-19 has been fully enrolled ahead of schedule.
Arcturus Therapeutics Reports Q4 Earnings, Shares Jump 30%
Arcturus Therapeutics (NASDAQ:ARCT) saw a 30% surge in its share prices yesterday after reporting Q4 results. The company's revenue for the quarter was $160.3 million, a significant increase from $13.4 million in Q4/22. The boost in revenue was primarily due to the $200 million upfront payment from CSL Seqirus as part of their exclusive global collaboration and license agreement for next-generation mRNA vaccines.
Arcturus is eligible for potential development and commercial milestones of up to $4.3 billion, with 40% profit sharing for COVID-19 vaccines and up to low double-digit royalties on influenza vaccine revenues.
Joseph Payne, the President and CEO of Arcturus Therapeutics, reported that the Phase 3 study conducted by Meiji Pharma to evaluate ARCT-154 as a booster vaccine for COVID-19 has been fully enrolled ahead of schedule.
